Destruction of intact cellular proteins is largely orchestrated by ATP-dependent ubiquitination and subsequent degradation by the 26S proteasome. The REG-20S proteasome, however, only degrades short peptides. In this issue of Cell, Li et al. (2006) challenge this notion by revealing that the proteasomal activator REGγ directs degradation of the steroid receptor coactivator SRC-3 by the 20S proteasome in an ATP-and ubiquitin-independent manner.
The proteasome is a major nonlysosomal proteolytic apparatus that destroys damaged or misfolded proteins as well as regulators governing fundamental cellular processes such as the cell cycle, transcription, cell signaling, cell death, and the immune response (Goldberg, 2003) . The catalytic core of this large multisubunit proteolytic complex is the 20S proteasome, which consists of 14 α and 14 β subunits arranged in a cylindrical particle of four heptameric rings with a central channel of 17Å in diameter and resembles a barrel. Two inner β rings harbor all of the proteolytic sites for substrate cleavage inside the central catalytic chamber, whereas two outer α rings provide the gated entry sites for substrate peptides. The 20S proteasome is a latent protease complex, as the N-terminal tails of α subunits occlude the central proteolytic channel. Activation of the 20S proteasome is achieved by either the 19S (PA700 or RC) regulatory particle (to form the 26S proteasome) or the 11S (REG or PA28) regulator, both of which associate with the top or bottom surface of the 20S "barrel" to trigger opening of the gate to allow entry of unfolded substrates. The REG/11S particle consists of REG subunits that are also arranged in a ring-shaped heptameric complex (Rechsteiner and Hill, 2005) . Of the three REG family members, REGα can form either homoheptamers or heteroheptamers with REGβ throughout the cell to participate in MHC class I antigen presentation. In contrast, REGγ (also called Ki antigen or PSME3) resides primarily in the nucleus in a homoheptameric form, and its function has remained largely elusive. In this issue of Cell, Li et al. (2006) provide evidence that the REGγ-20S complex is capable of selectively targeting an intact substrate-in this case, the nuclear receptor SRC-3-for destruction. During the investigation of the homeostasis of steroid-hormone receptors and coactivators, Li et al. (2006) discovered that REGγ interacts selectively with SRC-3, a member of the p160 nuclear receptor coactivator family involved in transcriptional regulation of genes activated through steroid receptors (Liao et al., 2002) . Overexpression of REGγ accelerated the turnover rate of SRC-3, whereas silencing REGγ expression with small interfering RNAs (siRNAs) resulted in accumulation of SRC-3 protein, suggesting an unexpected role for REGγ in determining the stability of an intact protein in vivo.
The most striking feature of the Li et al. (2006) study is the biochemical evidence for an unconventional mode of SRC-3 degradation by the REGγ-20S proteasome, which was thought only to hydrolyze small peptides (Rechsteiner and Hill, 2005) . In a cell-free proteasome proteolysis assay, fulllength SRC-3 was degraded in the presence of the 20S proteasome and heptameric REGγ without exogenous ATP or ubiquitin pathway components. The REGα/β complex did not promote the degradation of SRC-3. Furthermore, the closely related SRC-1, which is incapable of binding to REGγ, was resistant to REGγ-mediated degradation. These data provide compelling evidence for the presence of an alternative mechanism of targeting an intact protein to a distinct REGγ-20S proteasome complex for destruction.
This unexpected finding by Li et al. (2006) may provoke reassessment of the biochemical properties and physiological functions of the REG-20S proteasome. Unlike the 19S complex, the REG heptamer does not contain ATPase subunits to catalyze protein unfolding and translocation into the 20S particle. SRC-3 is a 160 kDa protein that contains distinct structural motifs, including a bHLH-PAS domain in the N terminus and a histone acetyltransferase (HAT) domain in the C terminus that is specifically responsible for binding to REGγ. Given that ATP and "reverse chaperones" were absent in the cell-free proteolytic assay, it is unclear how the individual domain structures unfold to yield the linear polypeptide chain for threading into the central proteasome channel for proteolytic cleavage.
An intriguing hypothesis is that SRC-3 degradation is not mediated by conventional unfolding and processive threading of its free N or C terminus into the proteasome. Rather, internal unstructured sequences of SRC-3 may serve as endoproteolytic sites for entry into the central opening of the REGγ-20S complex. Interestingly, an endoproteolytic activity has been revealed for the 20S proteasome, which cleaves at internal peptide bonds of naturally unfolded or unstructured proteins, including the cyclin-dependent kinase inhibitor p21 cip1 and α-synuclein (Liu et , 2003) . Furthermore, the Y box protein-1 and translation initiation factors eIF4G and eIF3a were recently shown to undergo limited proteolysis by the 20S proteasome through internal endoproteolytic sites in the absence of ATP and ubiquitin (Baugh and Pilipenko, 2004; Sorokin et al., 2005) . The internal SRC-3 sequences are predicted to be disordered with long loops as well as a polyglutamine loop. Additionally, the extreme amino-terminal 38 residues and carboxy-terminal 147 residues are also unstructured. It is possible that these disordered regions of SRC-3 may serve as cleavage sites for the 20S proteasome. The highly structured bHLH-PAS and the HAT domains, however, may be too large to enter the 20S proteasome in the absence of ATP-and reversechaperone-mediated unfolding. Determining the nature of the proteolytic products generated by the REGγ-20S proteasome would shed light on whether the 160 kDa SRC-3 protein is completely digested or only partially cleaved through internal or terminal unstructured sites. Although protein substrates subjected to endoproteolytic cleavage by the 20S proteasome in vitro often contain either overall or locally disordered structural features, they share little sequence similarity. Therefore, it is currently unclear whether this endoproteolytic activity of the 20S proteasome possesses any substrate specificity in vivo. However, the REGγ-20S proteasome appears highly selective for SRC-3 as SRC-1, SRC-2, and estrogen receptor α are not subject to REGγ-mediated turnover. Such specificity suggests that the REGγ-20S proteasome does not indiscriminately degrade substrates with disordered elements. Given the ATP-independent nature of SRC-3 degradation, a potential benefit of the physical interaction between REGγ and SRC-3 is to facilitate entry of natively disordered sites of SRC-3 into the central proteolytic chamber of the associated 20S proteasome. Introduction of a substrate selection step would impose a limitation on which cellular proteins have access to this alternative proteolytic pathway.
The study by Li et al. (2006) provides intriguing evidence for a new function of REGγ in directing SRC-3 to the 20S proteasome for destruction. However, compared to the robust activity of the 20S proteasome in the endoproteolytic cleavage of unstructured proteins (Liu et al., 2003) , both in vitro and in vivo degradation of SRC-3 mediated by REGγ is noticeably less efficient, with only a 2- to 3-fold decrease in the amount of SRC-3. Interestingly, SRC-3 is known to be modified by ubiquitin and subjected to degradation by the 26S proteasome (Lonard et al., 2000) . The extent of the relative contributions or interplay of ubiquitin-dependent and -independent processes on SRC-3 stability during steroid-hormone receptor-induced gene expression and cell growth remain unclear.
The requirement for precise control of SRC-3 abundance is underscored by the robust growth-promoting role of this steroid receptor coactivator in mammary-gland development and its potent activity in promoting transformation and breast tumor formation (Liao et al., 2002) . Abnormal expression of SRC-3 has been reported in 50 to 60% of breast cancers. In parallel with the accumulation of SRC-3 levels upon treatment of cells with siRNAs against REGγ, Li et al. (2006) observed an increase in expression of estrogenregulated genes and an enhancement of estrogen-dependent cell growth. Interestingly, a recent serial analysis of gene expression (SAGE) study identified a 15.7-fold reduction in REGγ expression in ductal carcinoma compared to normal breast tissue (Abba et al., 2004) . Taken together, these data suggest a potential tumor-suppressive role for REGγ in breast carcinogenesis by restricting the uncontrolled accumulation of SRC-3.
Given the growth-retardation phenotype of REGγ-deficient mice and the defects in cell-cycle progression seen in REGγ-deficient mouse embryonic fibroblasts (Murata et al., 1999) , the observed growth inhibition by REGγ in estrogen-dependent cells is likely to be only the tip of an intriguing iceberg regarding REGγ-mediated proteolysis. Several REGγ binding proteins have been implicated in apoptosis and REGγ-deficient fibroblasts are prone to apoptosis. These observations have lead to the proposal that REGγ may block apoptosis, possibly by promoting degradation of target proteins (Rechsteiner and Hill, 2005) . Indeed, overexpression of REGγ accelerates degradation of the hepatitis C virus core protein (Moriishi et al., 2003) . The study by Li et al. (2006) provides a starting point to explore the biochemical mechanism by which REGγ targets degradation of intact protein substrates. Future studies should address the scope, biochemical basis, and biological functions of this new mode of direct protein targeting to the 20S proteasome.
